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Abstract
Background: Being able to make an estimation of the time to clinical outcome, and making predictions early during treatment about the possibility of later 
response/non-response to treatment, is an important asset that can help to guide treatment strategies and counsel patients and caregivers about treatment 
expectations. Objectives: The study aimed to determine the time course to treatment outcome and the psychopathological cut-off score at week 4 that predicts 
outcome at week 16. Methods: This was a naturalistic follow-up study of 160 incident cases of schizophrenia over 16 weeks. Four intervals of follow-up clinical 
assessments were done. Standard criteria for response and remission were applied. Results: The mean (median) times, in weeks, to response and remission 
using Brief Psychiatric Rating Scale (BPRS) data were 8.1(8.0); 8.4(8.0); and 10.9 (12.0), respectively. The Areas Under the Curves were high, for response 
(0.909; 95% C.I., 0.85-0.97) and remission (0.86; 95% C.I., 0.81 -0.94) at week 16. A cut-off score of 20.7% reduction in the total BPRS score at week 4, predicted 
response status (79.5% sensitivity, 84.2% specificity) and remission status (77.6% sensitivity, 73.3% specificity) at week 16. In addition, a cut-off of 10.21% 
reduction in the total Scale for Assessment of Negative Symptoms (SANS) score at week 4, predicted response (70.8% sensitivity, 95.5% specificity) at week 
16. Discussion: The results are in line with the general clinical impression that, by 2 months, most acutely ill inpatients are fit for discharge; and introduced 
for further investigation 10.21% reduction in SANS Score as a marker of treatment resistance in schizophrenia. 
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Introduction
Schizophrenia is a disorder with varied pathophysiology and 
heterogeneous treatment outcome across cultures1. Being able to make 
an informed estimation about the time to clinical outcome events 
(i.e., response, remission and recovery), and making predictions 
early during treatment about the possibility of later response/
non-response to treatment among patients with schizophrenia, is 
an important asset that can help to guide treatment strategies and 
counsel patients and caregivers about treatment expectations2. The 
best guide for such estimates is one derived from follow-up studies 
of first- episode patients.
Many factors are considered when making decisions on the 
optimum duration of therapeutic trial either in clinical or research 
situations among schizophrenia patients. An important consideration 
is balancing the negative consequences of prematurely terminating 
a therapeutic trial, with the negative consequences of prolonging an 
ineffective treatment3. In Africa, there is dearth of data that suggest 
how long a therapeutic trial should last, or what volume or percentage 
of symptom reduction early in treatment predicts response/non-
response later on in treatment. Emsley et al.4 and Lieberman et 
al.5 found that the median time to response and remission among 
schizophrenia patients on treatment was 3 and 11 weeks, respectively. 
Correll et al.2 found that failure to achieve 20% improvement in 
symptoms after 1 week predicted non-response after 4 weeks. In 
addition, Kane et al.6,7 in their widely accepted definition of drug-
refractoriness pegged treatment non-response as failure to achieve at 
least 20% reduction in the total Brief Psychiatry Rating Scale (BPRS) 
score by 6 weeks of optimal treatment. However, Gallego et al.8 using 
receiver operating characteristics analyses did not find any level of 
percent symptom reduction that was clinically useful as a predictor 
of response by week 16. 
The validity of these observations has not been tested in African 
populations, where the clinical manifestations and treatment 
outcome have been postulated to be different from Caucasian 
populations9-11. Using standard operational definitions6,12,13, this 
study aimed to estimate the mean and median times to treatment 
response, remission and recovery, as well as the early response cut-off 
in percentage reduction of symptoms that would predict response/
remission/recovery at 16 weeks of naturalistic follow-up of a cohort 
of Nigerian patients with first-episode schizophrenia. 
Subjects and methods
Details about the recruitment of patients, operational definitions, 
assessment for family history of illness, follow-up and clinical outcome 
(response/ remission/ social recovery) are being presented elsewhere 
(Onu & Ohaeri, In Press). This was a naturalistic longitudinal follow-
up outcome study which took place at the Federal Neuropsychiatric 
Hospital (FNH), Enugu, Nigeria. Participants were recruited from 
April to July 2016. Consecutive incident cases of schizophrenia, who 
presented at the hospital, aged 18-49 years, and resident within Enugu 
metropolis (to facilitate follow-up) were invited, with their available 
family members, to participate in the study. Patients with schizophrenia 
of suspected organic aetiology, including substance use disorders, 
medical or psychiatric co-morbidities, or both, were excluded. 
Diagnosis of schizophrenia was confirmed using Mini International 
Neuropsychiatric Interview (MINI)14. Patients were assessed at baseline 
and followed up at intervals of 4 weeks for 16 weeks. Symptom changes 
and functional status were assessed at baseline and at each interval of 
treatment follow-up, using the Brief Psychiatry Rating Scale (BPRS)15, 
Scale for Assessment of Negative Symptoms (SANS)16, as well as 
Global Assessment of Functioning (GAF)17, and the World Health 
Organization Disability Assessment Scale (WHODAS)18, respectively.
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Treatment response, remission and recovery: Response was 
defined as symptom reduction greater than 50% of the baseline 
scores in BPRS and SANS scores during each period of follow-up13. 
Symptomatic remission was defined as a rating of ‘mild’ or less, 
concurrently on the following seven BPRS items (BPRS only criteria): 
grandiosity, suspiciousness, unusual thought content, hallucinatory 
behavior, conceptual disorganization, mannerism/posturing, and 
blunted affect13. In addition, as suggested by Andreasen13 when using 
SANS, a score of 2 or less on the following 4 SANS items: affective 
flattening, avolition-apathy, anhedonia-asociality, and alogia (SANS 
criteria).  Functional or social recovery (also termed functional 
remission) was based on both clinical and psychosocial functional 
dimensions as proposed by Jaaskelainen et al.12. Hence, social 
recovery in this study was defined as: (a) maintaining symptomatic 
remission as described above through the particular follow-up 
period; and (b) having a GAF score greater than or equal to 61. 
This GAF score indicates that the subject is judged to be capable 
of returning to the premorbid level of psychosocial functioning17.
Mode of onset of illness was dichotomized as: acute vs. chronic 
(insidious). Acute onset means that the positive symptoms of 
schizophrenia dramatically rose to a crescendo within one month, 
with a sudden deterioration from the premorbid level of functioning 
in that period. Insidious onset means that there was a gradual 
deterioration in premorbid level of functioning that spread over 
several months, along with the appearance of negative symptoms, 
while the onset of positive symptoms was slow and occurred after a 
period of noticeable change in premorbid functioning19.
Family history of mental illness was assessed with the Family 
Interview for Genetic Studies20. The FIGS was developed by principal 
investigators in the National Institute of Mental Health (NIMH) 
Schizophrenia and Bipolar Disorder Genetics Initiatives and NIMH 
extramural program staff in 1992, as a guide for systematically 
collecting information about relatives in family genetic studies of 
these disorders.
Ethical considerations 
Ethical approval was obtained from the Ethical Committee of the 
Federal Neuropsychiatric Hospital Enugu, Enugu State, Nigeria. 
International ethical norms and standards were strictly adhered to. 
After explaining the objectives and procedures, consenting patients 
were required to sign the written informed consent, with the 
understanding that they could withdraw from the study at any stage 
without any adverse impact on their right to treatment.
Data analysis
Mean and median times to response, remission and recovery 
were estimated using Kaplan-Meier survival analysis, which also 
estimated significant differences in time to event for variables, such 
as: gender, family history of illness, mode of onset of illness, and 
adequacy of social support in the cohort. Significant differences in 
time to outcome event between categories of subjects (e.g., male/
female, satisfactory/non-satisfactory social support, family history 
of illness, and age at onset of illness) were assessed by the log rank 
(Mantel-Cox), Breslow (generalized Wilcoxon) and Tarone-Ware. 
However, we present the Breslow results because they were similar to 
the others. For the ROC analyses (i.e., the early percentage reduction 
in total BPRS cut-off score that would predict outcome at week 16), 
we used the response at week 4, versus, the outcome at week 16. This 
was because the first follow-up assessment was at week 4, in line with 
the recommendation of Trivedi et al.21.
Results
The socio-demographic and some clinical characteristics of the 160 
participants shows that they were mostly young (mean age 31.13 
± 12.50), and the mean age at onset of schizophrenia and duration 
of illness were 26.33 ± 12.15 years and 63.18 ± 74.15 months, 
respectively. Majority (51.2%) were females, never married (66.3%), 
with at least high school education (74.4%), and unemployed 
(63.8%). The attrition rate at week 16 was 29.4%; hence 113 subjects 
(out of 160) were available for assessment of response, remission 
and recovery at that time. Table 1 shows that, for the BPRS data, the 
mean (median) times, in weeks, to response, remission and recovery, 
were, respectively: 8.1 (8.0); 8.4 (8.0); and 10.9 (12.0). The equivalent 
results using SANS criteria were as follows: 9.1 (8.0); 9.4 (8.0); and 
11.1 (12.0), respectively. The tendency for longer mean time to 
response, remission and recovery for SANS, vs. BPRS, did not reach 
significance (Standardized Effect Size for response: 0.19, 95% CI: 
0.06-0.44). There were no significant differences in gender (Tables 
2-4; Figure 1), marital status and employment status (Tables 2-4) in 
times to response, remission and social recovery. However, there was 
a tendency for those who were married and employed to have shorter 
time to these outcome events (For the BPRS data only, employment 
status was associated with earlier time to recovery – P < 0.05: Table 4). 
These indices of social advantage were manifest as significantly 
shorter time to response (p < 0.001) (Table 2) and recovery (p < 0.04) 
(Table 4) for subjects with perception of satisfactory social support.
Subjects with acute onset of illness had significantly shorter time 
to response (p < 0.05) (Table 2) and remission (p < 0.005) (Table 3), 
than those with insidious onset. The tendency for those with no 
family history of mental illness to have shorter time to response and 
remission, did not reach significance (p > 0.05). 
For the ROC analyses (Figures 1a and 1b), using BPRS data for 
response at week 4 to predict outcome at week 16, the Areas Under 
the Curves (AUC) met the recommended cut-off for significance, 
for response (0.901, 95% CI: 0.85-0.963), remission (0.875; 95% CI: 
0.811-0.938) and recovery (0.874; 95% CI: 0.84-0.944) at week 16. In 
addition, the cut-off score of 20.7% reduction in BPRS score at week 
4, predicted response (79.5% sensitivity, 84.2% specificity), remission 
(77.6% sensitivity, 73.3% specificity) and recovery (88% sensitivity, 
67.7% specificity) at week 16. The equivalent AUC values (95% CI) 
for the SANS data were: 0.897 (0.84-0.935), 0.84 (0.775-0.919), 0.874 
and (0.804-0.944), respectively, for response, remission and recovery. 
Also, a cut-off of 10.21% reduction in SANS total score at week 4, 
predicted response (70.8% sensitivity, 95.5% specificity), remission 
(70.8% sensitivity, 91.9% specificity) and recovery (78.0% sensitivity, 
82.7% specificity) at week 16.
Discussion
The highlights of the findings of this 16-week naturalistic follow-up 
study of a Nigerian schizophrenia cohort are: (1) the mean (median) 
Table 1. The mean and median time to response, remission and recovery among schizophrenia patients: survival analyses
Outcome Using BPRS Criteria Using SANS Criteria
Mean in weeks (95% CI) Median in weeks (95% CI) Mean in weeks (95% CI) Median in weeks (95% CI)
Response 8.1(7.2-9.0) 8.0 (6.7-9.3) 9.1(8.2-10.1) 8.0 (6.5-9.5)
Remission 8.4 (7.5-9.2) 8.0 (7.0-9.0) 9.4 (9.0-9.5) 8.0 (6.9-9.5)
Recovery 10.9 (9.9-11.7) 12.0 (10.6-13.4) 11.1 (10.3-11.7) 12.0 (10.5-13.3)
NB: Response is defined as ≥50% reduction in total BPRS & SANS scores, Remission using BPRS = Scores ≤ 2 in psychosis BPRS items (grandiosity, suspiciousness, unusual thought content, 
hallucinatory behaviour, conceptual disorganization, mannerism/posturing, and blunted affect). Using SANS, a score of 2 or less on the following 4 SANS items: affective flattening, avolition-apathy, 
anhedonia-asociality, and alogia. Recovery = maintenance of remission + GAF-score ≥ 61.
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times, in weeks, to response, remission and social recovery were 
8.1(8.0); 8.4(8.0); and 10.9 (12.0), respectively, for the BPRS data, vs. 
9.1(8.0), 9.4 (8.0) and 11,1 (12.0), for the SANS data; (2) the time to 
response, remission and recovery differed with regards to baseline 
variables such as social support and mode of onset of illness; (3) the 
tendency for longer mean time to response, remission and recovery 
for negative symptoms, did not reach significance (Standardized 
Effect Size for response: 0.19, 95% CI: 0.06-0.44); (4) early response 
at week 4 significantly predicted 16-week response, remission and 
recovery; and (5) a threshold for early response of ≥20.7% BPRS-
score reduction and ≥10.21% for the SANS at week 4  had significant 
predictive validity for later response, remission and recovery 
For the survival analyses, our choice of 4 weeks as the first 
outcome assessment is in line with the American Psychiatric 
Association’s practice guideline recommendation that an initial 
trial of 4-6 weeks generally is needed to determine if the patient 
will have any symptomatic response, although symptoms can 
continue to improve over longer periods of time22,23. Understandably, 
our mean/median time to response, based on >50% reduction in 
psychopathology, is higher than the results for studies where response 
was defined as >20% reduction, and median time to response was 
3 weeks2. Furthermore, although our patients were incident cases, 
the mean duration of untreated psychosis was long (about 5 years), 
a factor that has been consistently associated with poor treatment 
response24,25. Perkins et al. found that shorter duration of untreated 
psychosis was associated with greater response to antipsychotic 
treatment, as measured by severity of global psychopathology, 
positive symptoms, negative symptoms and functional outcome26. 
However, our findings on time to response and remission support 
a recent recommendation by Kane et al. on guidelines for defining 
Table 2. Time to Response: by baseline independent variables among schizophrenia patients
Variables Time to Response Using BPRS Criteria Time to Response Using SANS Criteria









































































NB: response is defined as ≥50% reduction in total BPRS and SANS score; SE: standard error. 
Statistical significance was based on Breslow (generalized Wilcoxon). 
Table 3. Time to Remission: by baseline independent variables among schizophrenia patients
Variables Time to Remission Using BPRS Criteria Time to Remission Using SANS Criteria









































































NB: remission using BPRS = Scores ≤ 2 in the following BPRS items (Grandiosity, Suspiciousness, unusual thought content, Hallucinatory behavior, conceptual disorganization, mannerism/posturing, 
and blunted affect). Remission in SANS = Scores ≤ 2 in the following SANS items (Affective flattening, Avolition-apathy, Anhedonia-asociality, and Alogia). SE: standard error. Statistical significance 
was based on Breslow (generalized Wilcoxon). 
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treatment resistance among schizophrenia patients that suggest a 
treatment duration of ≥6 weeks and ≤12 weeks to re-evaluate for 
non-response to treatment7. This is in line with recent evidence 
indicating that with prolonged treatment, most patients with 
acute schizophrenia would respond to treatment8. Consistent with 
the literature, the negative symptoms in SANS tended to confer 
longer time to treatment outcome, although the effect size was not 
significant; and the early achievement of response in SANS score was 
associated with good clinical outcome at week 1627-30. 
Our findings on social support and acute onset of illness 
are consistent with other studies that have found that adequate 
social support and acute onset are promotive of early response 
to treatment31,32. Other factors reported in the literature include: 
employment, a shorter duration of illness, female sex, being married, 
younger age, tertiary education, and shorter duration of untreated 
psychosis24. Our results did not support the later findings, although 
there were trends in that direction for being married and being 
employed, factors which could be viewed as contributing to social 
Table 4. Time to Social Recovery: by baseline independent variables among schizophrenia patients
Variables Time to Recovery Using BPRS Criteria Time to Recovery Using SANS Criteria









































































NB: recovery = maintenance of remission + GAF-score ≥61, SE: standard error. Statistical significance was based on Breslow (generalized Wilcoxon). 
Figure 1a. Receiver Operating Characteristics curve showing plot of % 
reduction in total BPRS score at week 4 vs. response status (responded/not 
responded) at week 16. Note: Area under the curve (AUC) (95% C.I.): 0.909 
(0.85-0.963). With 20.72% BPRS reduction at week 4, prediction of response 
status at week 16 had 79.5% sensitivity, 84.2% specificity.
Figure 1b. Receiver Operating Characteristics curve showing plot of % 
reduction in total SANS score at week 4 vs. response status (responded/not 
responded) at week 16. Note: Area under the curve (AUC) (95% C.I.): 0.897 
(0.84-0.955). With 10.21% SANS reduction at week 4, prediction of response 































Diagonal segments are produced by ties.
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support. The long held impression is that the traditional social 
support in the African extended family system constitutes a huge 
social capital for patients with schizophrenia, and could positively 
modify the clinical course of the disease33,34. 
For the ROC analyses, we found that early response to treatment at 
week 4 predicted good response at week 16. This is consistent with Agid 
et al.35 early-onset of response hypothesis of antipsychotic drug action, 
which suggests that early response to medication is a stable predictor 
of subsequent response. Studies have evaluated the predictive value 
of early response to treatment among schizophrenia patients36-38. The 
results largely agree that, early response is a significant predictor of later 
response4,5,38. However, variations exist on which week of treatment has 
the best predictive validity for response at later stages of treatment36. 
Studies have evaluated response at weeks 1, 2, 3, 4, and 8. Although 
there is much support for the predictive value of response at 2 weeks4,5,36, 
it has been suggested that the first critical decision point for assessing 
treatment outcome is 4 weeks23, and this has been incorporated in 
treatment guidelines22,23. In line with our findings, Gallegos et al.8 
reported that early response at week 4 (not 2 or 8) was associated with 
responder status at week 16. Taken together, our data support the 
impression that re-evaluation of treatment in schizophrenia patients 
for response should occur within the first 4 weeks of commencing 
treatment, to identify potential candidates for treatment resistance 
early on in the treatment trajectory. In addition, our finding of ≥20.7% 
BPRS-score reduction at week 4 as having significant predictive 
validity for outcome events is consistent with the literature38. This 
finding validates the recommendation of Kane et al.6, that treatment 
resistance be defined as <20% reduction in BPRS total score after 
adequate psychopharmacological treatment. An important addition 
to the literature is the finding that ≥10.21% SANS-score reduction at 
week 4 was predictive of response, remission and recovery at week 16. 
Negative symptoms have been identified as important 
determinants of psychosocial functioning in schizophrenia27-29. In 
the prediction of global psychosocial functioning, negative symptom 
severity was the most important factor30. 
Limitations and strengths
First, being a naturalistic study (as distinct from a drug trial), 
we could not control treatment decisions, such as dosage/type of 
medications, and whether to augment or change medication when 
there was inadequacy of response. However, this design is in line with 
the international follow-up studies in the literature, and makes our 
results comparable with those studies. Second, treatment adherence 
was judged only by the verbal testimony of patients and family 
caregivers. Although this is less rigorous than assaying blood levels 
of drugs, our experience is that the accompanying family caregivers 
could be trusted to determine treatment adherence, Third, the 
relatively high attrition rate meant that we could not account for 
the outcome in over a quarter of the original cohort. We note that 
attrition is a well-known problem in follow-up studies, and we tried 
to avoid this problem by including only patients living within the 
metropolis of our study area. The major strengths of the study are 
that: first, we have used rigorous statistical methods and stringent 
operational definitions of clinical outcome, for incident cases, who 
were predominantly neuroleptic naïve at baseline, to estimate the time 
to outcome events. Second, we have validated the psychopathological 
cut-off points that define treatment resistance in schizophrenia. In 
particular, in addition to the well- known 20% cut-off for the BPRS, 
we have indicated that 10.21% be considered for the SANS
Conclusions
The results are in line with the general clinical impression that, by 
2 months, most acutely ill inpatients are fit for discharge in our 
practice setting; and support the popular use of  <20% reduction in 
BPRS psychopathological score, as a marker of treatment resistance 
in schizophrenia. We suggest that future studies could try to validate 
our finding of <10.21% reduction in SANS score as a marker of 
treatment resistance. In the first such rigorously designed study from 
Africa, this cohort of Nigerians with first – episode schizophrenia, 
had similar treatment response patterns, in the short-term, with such 
patients in the international literature.
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